Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2082946
Abstract: ABSTRACT Introduction Several patients with myasthenia gravis (MG) do not adequately respond to available drugs or exhibit poor tolerance, necessitating the need for new therapies. Areas covered The paper discusses the rapidly evolving target-specific immunotherapies… read more here.
Keywords: myasthenia gravis; complement anti; complement; complement therapeutics ... See more keywords
P0391STUDY OF ANTI COMPLEMENT FACTOR H MEDIATED DISEASE AT A TERTIARY CARE CENTRE
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0391
Abstract: To study the clinical profile and outcome of patients with anti complement factor H mediated disease at our centre. We conducted a prospective study over 24 months ( August 2016 to July 2018) to assess… read more here.
Keywords: factor; complement factor; anti complement; mediated disease ... See more keywords
Characterizing the original anti‐C5 function‐blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1111/imm.13228
Abstract: The implication of complement in multiple diseases over the last 20 years has fuelled interest in developing anti‐complement drugs. To date, the focus has been on C5; blocking cleavage of C5 prevents formation of two… read more here.
Keywords: original anti; antibody; characterizing original; anti complement ... See more keywords
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0723
Abstract: Development of novel therapeutic antibodies that not only kill tumor cells but modulate the adaptive immune response has the potential to produce long term anti-cancer immunity and a durable clinical response. We previously reported the… read more here.
Keywords: tumor cells; complement factor; anti complement; tumor ... See more keywords
The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.926044
Abstract: ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis (AAV) is the condition in which ANCA, as an autoantibody, is associated with the pathogenesis of vasculitis in small blood vessels, mainly in the ear, nose, throat, kidney, lung, and… read more here.
Keywords: vasculitis; complement; associated vasculitis; anti complement ... See more keywords